This study focuses on patients with overt hepatic encephalopathy, a condition that affects brain function due to advanced liver disease. The condition occurs in people who have liver cirrhosis with sudden worsening of symptoms or acute complications. The study will test a new investigational medicine called VS-01, which is given as a suspension through the abdominal cavity, in addition to regular standard treatment.
The purpose of this research is to determine if VS-01 can help treat overt hepatic encephalopathy when given once daily for up to 4 days. The study will compare two different treatment durations (3 hours and 4 hours) of VS-01 combined with standard care against standard care alone. The medication contains citric acid as its main component and is administered through intraperitoneal delivery, which means it is given directly into the abdominal cavity.
During the study, patients will receive either VS-01 with standard treatment or standard treatment alone. The treatment period lasts up to 4 days, during which doctors will monitor how quickly patients’ symptoms improve. The study will also look at how the body processes the medication and track any changes in blood and abdominal fluid composition to ensure the treatment is safe.



Belgium
France
Germany
Spain